The Management of degenerative lumbar spine disease
…incidence of low back pain is estimated at 5%, but only 1% develops radiculopathy [1]. Lumbar disc prolapse is a disease most common between 30 and 50 years of age,…
Content Section: Articles
…incidence of low back pain is estimated at 5%, but only 1% develops radiculopathy [1]. Lumbar disc prolapse is a disease most common between 30 and 50 years of age,…
Content Section: Articles
…(PPMS). Available at: https://www.mssociety.org.uk/what-is-ms/types-of-ms/primary-progressive-ppms. Last accessed June 2018. [xviii] Multiple Sclerosis Trust. Disease modifying drugs. Available at: https://www.mstrust.org.uk/understanding-ms/ms-symptoms-and-treatments/disease-modifying-drugs-ms-decisions/disease-modifying#work. Last accessed June 2018. [xix] MS Society. Early treatment. Available at: https://www.mssociety.org.uk/earlytreatment….
Content Section: News Posts
…[6]. In a US study, women with Parkinson’s disease waited longer to be referred for specialist care than men [7]. These disparities require an urgent response from the biomedical research,…
Content Section: Event News
…College Neuromuscular Disease Symposium, and I will continue to do so until HEE remove it from the ‘mandated/optional course’ list. Established in 2001, this conference is held annually in the…
Content Section: Conference Reports
…Neuromuscular Disease, Chief, Neuromuscular Disorders Section, University of North Carolina School of Medicine and lead investigator in the RAISE trial. “These exciting results give us additional reason to believe that…
Content Section: News Posts
…Parkinson’s and Lewy body disorders.’ Professor Sonia Gandhi (UCL) spoke about her work to understand the cellular mechanisms of Lewy body disease, describing the use of induced pluripotent stem cells…
Content Section: Conference Reports
…build capacity in caring for people with neurological disorders in the African continent, where the burden of disease related to both communicable and non-communicable diseases of the nervous system is…
Content Section: Conference Reports
…2019 – Imcyse, a clinical-stage company developing active and specific immunotherapeutics for the treatment and prevention of severe chronic diseases, today announces the presentation of a poster describing results obtained…
Content Section: News Posts
…(prior disease-modifying therapy [DMT]), 82.4% (206/250) vs 18.6% (48/258) of early-disease, and 81.9% (212/259) vs 26.5% (67/253) of late-disease patients in ublituximab- vs teriflunomide-treated cohorts, respectively (P<0.0001 for all) The…
Content Section: News Posts
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.